Pharmafile Logo
Pharmafocus logo
Advanced Search

AveXis

Showing 8 posts of 8 posts found.

novartis_outside_1

British baby’s death not caused by Zolgensma says Novartis

September 19, 2019
Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy

Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …

News

Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

August 21, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …

News
novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

News
25482028522_7a08ece5bb_z1

Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal

August 13, 2019
Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc

Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …

News

Senators call on FDA to use “forceful response” against Novartis over faulty data scandal

August 12, 2019
Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma

Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …

News
novartis_window

Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma

August 7, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma

Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …

News
novartis_window

Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy

May 28, 2019
Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma

The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …

News

Novartis CEO makes mark with $8.7bn AveXis acquisition

April 9, 2018
Sales and Marketing AveXis, Novartis, biotech, drugs, gene therapy, pharma, pharmaceutical

Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024